Daniel Abler

Lorenz Achim Kuhn, Daniel Abler, Jonas Richiardi et al.

Brain Metastases (BM) are a large contributor to mortality of patients with cancer. They are treated with Stereotactic Radiosurgery (SRS) and monitored with Magnetic Resonance Imaging (MRI) at regular follow-up intervals according to treatment guidelines. Analyzing and quantifying this longitudinal imaging represents an intractable workload for clinicians. As a result, follow-up images are not annotated and merely assessed by observation. Response to treatment in longitudinal imaging is being studied, to better understand growth trajectories and ultimately predict treatment success or toxicity as early as possible. In this study, we implement an automated pipeline to curate a large longitudinal dataset of SRS treatment data, resulting in a cohort of 896 BMs in 177 patients who were monitored for >360 days at approximately two-month intervals at Lausanne University Hospital (CHUV). We use a data-driven clustering to identify characteristic trajectories. In addition, we predict 12 months lesion-level response using classical as well as graph machine learning Graph Machine Learning (GML). Clustering revealed 5 dominant growth trajectories with distinct final response categories. Response prediction reaches up to 0.90 AUC (CI95%=0.88-0.92) using only pre-treatment and first follow-up MRI with gradient boosting. Similarly, robust predictive performance of up to 0.88 AUC (CI95%=0.86-0.90) was obtained using GML, offering more flexibility with a single model for multiple input time-points configurations. Our results suggest potential automation and increased precision for the comprehensive assessment and prediction of BM response to SRS in longitudinal MRI. The proposed pipeline facilitates scalable data curation for the investigation of BM growth patterns, and lays the foundation for clinical decision support systems aiming at optimizing personalized care.

D. Abler, O. Pusterla, A. Joye-Kühnis et al.

Background: Radiomics shows promise in characterizing glioblastoma, but its added value over clinical and molecular predictors has yet to be proven. This study assessed the added value of conventional radiomics (CR) and deep learning (DL) MRI radiomics for glioblastoma prognosis (<= 6 vs > 6 months survival) on a large multi-center dataset. Methods: After patient selection, our curated dataset gathers 1152 glioblastoma (WHO 2016) patients from five Swiss centers and one public source. It included clinical (age, gender), molecular (MGMT, IDH), and baseline MRI data (T1, T1 contrast, FLAIR, T2) with tumor regions. CR and DL models were developed using standard methods and evaluated on internal and external cohorts. Sub-analyses assessed models with different feature sets (imaging-only, clinical/molecular-only, combined-features) and patient subsets (S-1: all patients, S-2: with molecular data, S-3: IDH wildtype). Results: The best performance was observed in the full cohort (S-1). In external validation, the combined-feature CR model achieved an AUC of 0.75, slightly, but significantly outperforming clinical-only (0.74) and imaging-only (0.68) models. DL models showed similar trends, though without statistical significance. In S-2 and S-3, combined models did not outperform clinical-only models. Exploratory analysis of CR models for overall survival prediction suggested greater relevance of imaging data: across all subsets, combined-feature models significantly outperformed clinical-only models, though with a modest advantage of 2-4 C-index points. Conclusions: While confirming the predictive value of anatomical MRI sequences for glioblastoma prognosis, this multi-center study found standard CR and DL radiomics approaches offer minimal added value over demographic predictors such as age and gender.